发明申请
- 专利标题： GENETIC RISK ASSESSMENT IN HEART FAILURE: IMPACT OF THE GENETIC VARIATION OF G-PROTEIN BETA 3 SUBUNIT POLYMORPHISM
- 专利标题（中）： 心脏遗传危险评估：G蛋白β亚基多态性遗传变异的影响
-
申请号： US12296630申请日： 2007-04-04
-
公开(公告)号： US20090306027A1公开(公告)日： 2009-12-10
- 发明人: Manuel Worcel , Michael Sabolinski , Sang W. Tam , Dennis M. McNamara
- 申请人： Manuel Worcel , Michael Sabolinski , Sang W. Tam , Dennis M. McNamara
- 申请人地址： US MA Lexington US PA Pittsburgh
- 专利权人： NitoMed, Inc.,Unversity of Pittsburgh of the Commonwealth System of the Higher Education
- 当前专利权人： NitoMed, Inc.,Unversity of Pittsburgh of the Commonwealth System of the Higher Education
- 当前专利权人地址： US MA Lexington US PA Pittsburgh
- 国际申请： PCT/US2007/008426 WO 20070404
- 主分类号： A61K31/56
- IPC分类号： A61K31/56 ; A61K31/34 ; A61K31/502
摘要：
The invention provides methods for treating various indications and diseases in a patient in need thereof, wherein the patient has a C825T polymorphism in the G protein beta3 subunit (GNB3), comprising administering to the patient (i) at least one antioxidant compound or a pharmaceutically acceptable salt thereof; (ii) at least one nitric oxide enhancing compound; and (iii) optionally the best current therapy for the treatment of cardiovascular diseases. In one embodiment the antioxidant is a hydralazine compound or a pharmaceutically acceptable salt thereof and the nitric oxide enhancing compound is isosorbide dinitrate and/or isosorbide mononitrate.
信息查询
